Literature DB >> 15574772

Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.

Andrew R Reynolds1, Louise E Reynolds, Tobi E Nagel, Julie C Lively, Stephen D Robinson, Daniel J Hicklin, Sarah C Bodary, Kairbaan M Hodivala-Dilke.   

Abstract

Tumor growth, tumor angiogenesis, and vascular endothelial growth factor (VEGF)-specific angiogenesis are all enhanced in beta(3)-integrin-null mice. Furthermore, endothelial cells isolated from beta(3)-null mice show elevated levels of Flk1 (VEGF receptor 2) expression, suggesting that beta(3)-integrin can control the amplitude of VEGF responses by controlling Flk1 levels or activity. We now show that Flk1 signaling is required for the enhanced tumor growth and angiogenesis seen in beta(3)-null mice. Moreover, beta(3)-null endothelial cells exhibit enhanced migration and proliferation in response to VEGF in vitro, and this phenotype requires Flk1 signaling. Upon VEGF stimulation, beta(3)-null endothelial cells exhibit higher levels of phosphorylated Flk1 and extracellular-related kinases 1 and 2 than wild-type endothelial cells. Furthermore, signaling via ERK1/2 is required to mediate the elevated responses to VEGF observed in beta(3)-null endothelial cells and aortic rings in vitro. These data confirm that VEGF signaling via Flk1 is enhanced in beta(3)-integrin-deficient mice and suggests that this increase may mediate the enhanced angiogenesis and tumor growth observed in these mice in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574772     DOI: 10.1158/0008-5472.CAN-04-2760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

Review 1.  VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy.

Authors:  Nader Rahimi
Journal:  Front Biosci       Date:  2006-01-01

2.  Endothelial von Willebrand factor regulates angiogenesis.

Authors:  Richard D Starke; Francesco Ferraro; Koralia E Paschalaki; Nicola H Dryden; Thomas A J McKinnon; Rachel E Sutton; Elspeth M Payne; Dorian O Haskard; Alun D Hughes; Daniel F Cutler; Mike A Laffan; Anna M Randi
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

3.  Regulation of lymphatic-blood vessel separation by endothelial Rac1.

Authors:  Gabriela D'Amico; Dylan T Jones; Emma Nye; Karen Sapienza; Antoine R Ramjuan; Louise E Reynolds; Stephen D Robinson; Vassiliki Kostourou; Dolores Martinez; Deborah Aubyn; Richard Grose; Gareth J Thomas; Bradley Spencer-Dene; Daniel Zicha; Derek Davies; Victor Tybulewicz; Kairbaan M Hodivala-Dilke
Journal:  Development       Date:  2009-12       Impact factor: 6.868

4.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.

Authors:  Tom T Chen; Alfonso Luque; Sunyoung Lee; Sean M Anderson; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2010-02-22       Impact factor: 10.539

6.  Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.

Authors:  Shu-Guang Li; Zai-Yuan Ye; Zhong-Sheng Zhao; Hou-Quan Tao; Yuan-Yu Wang; Chun-Yu Niu
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  Integrin affinity modulation in angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Juhua Chen; Weiyi Feng; Payaningal R Somanath; Olga V Razorenova; Tatiana V Byzova
Journal:  Cell Cycle       Date:  2007-11-01       Impact factor: 4.534

8.  Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

Authors:  Gabriela D'Amico; Stephen D Robinson; Mitchel Germain; Louise E Reynolds; Gareth J Thomas; George Elia; Garry Saunders; Marcus Fruttiger; Victor Tybulewicz; Georgia Mavria; Kairbaan M Hodivala-Dilke
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Authors:  Elizabeth A Morgan; Jochen G Schneider; Timothy E Baroni; Ozge Uluçkan; Emanuela Heller; Michelle A Hurchla; Hongju Deng; Desiree Floyd; Andrew Berdy; Julie L Prior; David Piwnica-Worms; Steven L Teitelbaum; F Patrick Ross; Katherine N Weilbaecher
Journal:  FASEB J       Date:  2009-11-20       Impact factor: 5.191

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.